Your browser doesn't support javascript.
loading
Current Status of Clinical Diagnosis and Genetic Analysis of Hereditary Hemorrhagic Telangiectasia in South Korea: Multicenter Case Series and a Systematic Review / 신경중재치료의학
Neurointervention ; : 91-98, 2019.
Article in English | WPRIM | ID: wpr-760598
ABSTRACT

PURPOSE:

Hereditary hemorrhagic telangiectasia (HHT), a rare genetic vascular disorder, has been rarely reported in South Korea. We investigated the current prevalence and presenting patterns of genetically confirmed HHT in South Korea. MATERIALS AND

METHODS:

We defined HHT patients as those with proven mutations on known HHT-related genes (ENG, ACVRL1, SMAD4, and GDF2) or those fulfilling 3 or 4 of the Curaçao criteria. A computerized systematic search was performed in PubMed and KoreaMed using the following search term (“hereditary hemorrhagic telangiectasia” AND “Korea”) OR (“Osler-Weber-Rendu” AND “Korea”). We also collected government health insurance data. HHT genetic testing results were collected from three tertiary hospitals in which the genetic tests were performed. We integrated patient data by analyzing each case to obtain the prevalence and presenting pattern of HHT in South Korea.

RESULTS:

We extracted 90 cases from 52 relevant articles from PubMed and KoreaMed. An additional 22 cases were identified from the three Korean tertiary hospitals after excluding seven cases that overlapped with those in the published articles. Finally, 112 HHT patients were identified (41 males and 71 females, aged 4–82 years [mean±standard deviation, 45.3±20.6 years]). The prevalence of HHT in South Korea is about 1 in 500,000, with an almost equal prevalence among men and women. Forty-nine patients underwent genetic testing, of whom 28 had HHT1 (ENG mutation) and 19 had HHT2 (ACVRL1 mutation); the other two patients were negative for ENG, ACVRL1, and SMAD4 mutations.

CONCLUSION:

The prevalence of HHT is underestimated in Korea. The rate of phenotypic presentation seems to be similar to that found worldwide. Korean health insurance coverage is limited to representative genetic analysis to detect ENG and ACVRL1 mutations. Further genetic analyses to detect HHT3, HHT4, and other forms of HHT should be implemented.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Arteriovenous Malformations / Telangiectasia, Hereditary Hemorrhagic / Epistaxis / Genetic Testing / Prevalence / Arteriovenous Fistula / Diagnosis / Tertiary Care Centers / Hemorrhage / Insurance, Health Type of study: Controlled clinical trial / Diagnostic study / Prevalence study / Prognostic study / Systematic reviews Limits: Female / Humans / Male Country/Region as subject: Asia Language: English Journal: Neurointervention Year: 2019 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Arteriovenous Malformations / Telangiectasia, Hereditary Hemorrhagic / Epistaxis / Genetic Testing / Prevalence / Arteriovenous Fistula / Diagnosis / Tertiary Care Centers / Hemorrhage / Insurance, Health Type of study: Controlled clinical trial / Diagnostic study / Prevalence study / Prognostic study / Systematic reviews Limits: Female / Humans / Male Country/Region as subject: Asia Language: English Journal: Neurointervention Year: 2019 Type: Article